BMS-202

**BMS-202** is a small molecule inhibitor that targets the programmed cell death ligand 1 (PD-L1), blocking its interaction with programmed cell death protein 1 (PD-1). This biphenyl scaffold derivative was developed by Bristol Myers Squibb for immuno-oncology applications. BMS-202 functions by binding to PD-L1, interrupting PD-1/PD-L1 signaling, and thereby reactivating immune cell antitumor activity. Preclinical studies have shown antitumor, immunomodulatory, and metabolic effects in several cancer models (including melanoma and glioblastoma), inhibition of cancer cell proliferation, migration, and invasion, and remodeling of cell metabolism via the PD-L1/AKT/BCAT1 pathway. BMS-202 also has shown potential in topical application for prophylaxis against UV-induced skin damage by antagonizing PD-L1 overexpression[1][2][3][5][7].

Other names

N-(2-((2-methoxy-6-(2-methyl-biphenyl-3-ylmethoxy)-pyridin-3-ylmethyl)-amino)-ethyl)-acetamide